Active, not recruitingPhase 3NCT06767735
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
Studying MODY
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gan & Lee Pharmaceuticals.
- Intervention
- GZR4(drug)
- Enrollment
- 580 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Gan & Lee Pharmaceuticals Shandong Co., Ltd., Linyi, Shandong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06767735 on ClinicalTrials.govOther trials for MODY
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT06609356Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 DiabetesVanderbilt University Medical Center
- RECRUITINGNANCT06118931Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic ControlUniversity of Toronto
- RECRUITINGPHASE2NCT07029009Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)Mansa
- RECRUITINGNANCT06267391Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II DiabetesEndogenex, Inc.
- RECRUITINGNANCT06337357Results of Progressive Resistance Training in Older Type 2 Diabetic Patients With SarcopeniaNational Geriatric Hospital
- RECRUITINGNCT06111833Optimized Diagnosis and Precision Medicine of MODYTaichung Veterans General Hospital
- RECRUITINGNCT07492004China Monogenic Diabetes RegistryTianjin Medical University General Hospital